Research Paper Volume 15, Issue 13 pp 6179—6211
ZNF765 is a prognostic biomarker of hepatocellular carcinoma associated with cell cycle, immune infiltration, m6A modification, and drug susceptibility
Figure 5. DNA methylation of ZNF765 in HCC. (A) Heatmap for ZNF765 in HCC. (B) The correlation between ZNF765 methylation and its expression level (n = 521). (C) A boxplot of ZNF765 promoter methylation levels in normal and HCC samples. (D) Boxplot demonstrating the relative promoter methylation level of ZNF765 in healthy people of any age or HCC patients aged 21–40, 41–60, 61–80, or 81–100 years. (E) A boxplot depicting the relative promoter methylation level of ZNF765 in healthy people and HCC patients of different genders. (F) Boxplot showing the relative promoter methylation level of ZNF765 in normal individuals or HCC patients in grades 1, 2, 3, or 4. (G) Boxplot depicting the relative promoter methylation level of ZNF765 in normal individuals with any nodal metastasis status or HCC patients with N0 and N1 nodal metastasis. ***p < 0.001.